Drug Discovery and Development Solutions for Cystic Fibrosis

Our In Vitro Efficacy Testing Service accelerates Cystic Fibrosis drug discovery by providing robust, sensitive platforms for screening and characterizing therapeutic candidates. We employ biochemical, cellular, and electrophysiological assays—including chemiluminescent, fluorescent, ELISA, patch-clamp, and short-circuit current methods—to measure compound potency and mechanism of action. Key targets such as CFTR and Adenosine A1 Receptor are evaluated in disease-relevant models. Quantitative parameters like EC-50 and Ki enable precise comparison and optimization of drug candidates, supporting lead selection and mechanistic insights to advance effective therapies for Cystic Fibrosis.

Protheragen delivers comprehensive animal model development services for Cystic Fibrosis, leveraging 56 validated models across eight species and 15 strains. Our expertise encompasses genetic engineering, chemical induction, and infection-based methodologies, including CRISPR/Cas9 and transgenic technologies. We offer end-to-end support, from model selection and customization to advanced endpoint analysis using molecular, imaging, and microbiological techniques. Rigorous quality control ensures reproducibility and data integrity. Our models recapitulate key CF pathologies, enabling robust therapeutic efficacy, mechanistic, and biomarker studies. Partnering with Protheragen accelerates translational research and drug development with scientifically robust, ethically compliant, and actionable results.

Our PK/PD research service for cystic fibrosis delivers comprehensive assessments of drug absorption, distribution, metabolism, and excretion, utilizing advanced analytical techniques such as HPLC, mass spectrometry, and radioactivity-based assays. We support multiple administration routes and conduct extensive compartment analysis across relevant tissues, including the lung and respiratory tract. Leveraging diverse animal models, our studies enable robust exposure-response characterization, dosing optimization, and interspecies scaling. This integrated approach ensures scientifically rigorous data to inform therapeutic design and accelerate clinical translation, offering a valuable resource for optimizing cystic fibrosis drug development and ultimately improving patient outcomes.

Protheragen offers comprehensive in vivo toxicity assessment services tailored for Cystic Fibrosis therapeutics, utilizing advanced methodologies and diverse animal models. Capabilities include acute and chronic toxicity studies, organ- and system-specific evaluations, and specialized investigations addressing CF-specific risks. Rigorous quality control, automated data collection, and adherence to ICH, OECD, and FDA standards ensure robust, reproducible results. Disease-relevant endpoints such as pulmonary function are incorporated for translational relevance. This integrated approach delivers reliable safety profiles, supports regulatory submissions, and empowers informed decision-making, positioning Protheragen as a trusted partner in the development of safe, effective Cystic Fibrosis treatments.

Protheragen offers research-focused biomarker analysis services supporting exploratory drug discovery in Cystic Fibrosis. We utilize integrated multi-omics platforms—including genomics, transcriptomics, proteomics, and metabolomics—to investigate molecular changes and screen candidates with potential as biomarkers. Our technical expertise encompasses advanced assay development, high-throughput quantitative analysis, and tailored evaluation methodologies. We assess the relevance and detectability of various targets in preclinical models, emphasizing rigorous analytical validation and reproducibility. All biomarker-related activities are conducted within a preclinical research context, enabling the evaluation and characterization of candidates that may inform future therapeutic development for Cystic Fibrosis.